glp 1 agonists vs sglt2 inhibitors Combining GLP-1 Receptor and in Type 2 Diabetes Mellitus: A Scoping Review and Expert Insights for Clinical Practice Utilizing the Nominal Group Technique | Diabetes Therapy Disparities in SGLT2 Inhibitor or

Description

Since pharmacological doses of GIPRAs have been found to exert anti-obesity and anti-inflammatory effects, it is tempting to propose that they could retard the atherosclerotic process and translate into reduction of adverse clinical outcomes

When you make healthy lifestyle changes in a medical setting with supportive resources like 1:1 virtual coaching, you can take control of your health and feel like your best self

The effectiveness of GLP-1 therapies depends not only on their pharmacological properties, but on the ability of patients to integrate them into their lives over the long term

The Phase 2 clinical trial of CagriSema which combined cagrilintide and semaglutide led to 15.6% weight reduction in T2DM patients while achieving superior glycemic control and better outcomes than each drug alone [53,54]